Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
4.615
+0.055 (+1.21%)
Streaming Delayed Price
Updated: 12:03 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
November 01, 2021
Via
Investor Brand Network
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
The Week In Psychedelics
Via
Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
October 24, 2021
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
October 29, 2021
Upgrades For Preferred Bank (NASDAQ:
Via
Benzinga
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
October 23, 2021
The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last.
Via
Talk Markets
Down 25% in 2021, Is Compass Pathways Undervalued?
October 22, 2021
It depends on how optimistic you are about its lead program.
Via
The Motley Fool
North America Continues Leading The Way In Psychedelic Wellness
October 26, 2021
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing...
Via
FinancialNewsMedia
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
October 20, 2021
Small Pharma Inc. (OTCQB:DMTTF) (TSXV:
Via
Benzinga
Psychedelic Unicorn Compass Pathways Receives New Patent Approval
October 20, 2021
Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedeli...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic
October 18, 2021
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
October 18, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
October 15, 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.
Via
Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
October 12, 2021
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.
Via
Talk Markets
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
October 12, 2021
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...
Via
FinancialNewsMedia
Why Compass Pathways Stock Dropped 12% in September
October 05, 2021
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.
Via
The Motley Fool
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
September 30, 2021
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,...
Via
FinancialNewsMedia
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
September 28, 2021
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
September 27, 2021
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
October 05, 2021
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to...
Via
FinancialNewsMedia
1 Recent Healthcare IPO to Put on Your Radar
September 24, 2021
Here's a pharmaceutical company that could have an incredibly bright future.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Is Ketamine A Psychedelic? Depends On Who You Ask
September 22, 2021
Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p...
Via
Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
September 22, 2021
Via
FinancialNewsMedia
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
September 21, 2021
We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses.
Via
Talk Markets
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
September 20, 2021
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares
Via
Benzinga
Which Psychedelic Stock ETF Is Right For You?
September 18, 2021
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.
Via
Talk Markets
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
September 15, 2021
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...
Via
Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
September 09, 2021
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.